In most clinical studies, the PD-L1 status of the tumor correlated with the overall clinical benefit of the PD-1 therapy, whereby PD-L1 positive patients responded better to PD-1 immunotherapy treatment, either alone or in combination with chemotherapy. The gene discussed is PDCD1; the disease is neoplasm.